320 related articles for article (PubMed ID: 26950722)
21. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans.
Backus LI; Belperio PS; Shahoumian TA; Loomis TP; Mole LA
Aliment Pharmacol Ther; 2015 Sep; 42(5):559-73. PubMed ID: 26113432
[TBL] [Abstract][Full Text] [Related]
22. HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR.
Michels FBL; Amaral ACC; Carvalho-Filho RJ; Vieira GA; Souza ALDS; Ferraz MLG
Arq Gastroenterol; 2020; 57(1):45-49. PubMed ID: 32294735
[TBL] [Abstract][Full Text] [Related]
23. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
[TBL] [Abstract][Full Text] [Related]
24. Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease.
Herzer K; Welzel TM; Spengler U; Hinrichsen H; Klinker H; Berg T; Ferenci P; Peck-Radosavljevic M; Inderson A; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
Transpl Int; 2017 Mar; 30(3):243-255. PubMed ID: 28012215
[TBL] [Abstract][Full Text] [Related]
25. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients.
Gutierrez JA; Carrion AF; Avalos D; O'Brien C; Martin P; Bhamidimarri KR; Peyton A
Liver Transpl; 2015 Jun; 21(6):823-30. PubMed ID: 25825070
[TBL] [Abstract][Full Text] [Related]
26. Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.
Dumortier J; Leroy V; Duvoux C; de Ledinghen V; Francoz C; Houssel-Debry P; Radenne S; d'Alteroche L; Fougerou-Leurent C; Canva V; di Martino V; Conti F; Kamar N; Moreno C; Lebray P; Tran A; Besch C; Diallo A; Rohel A; Rossignol E; Abergel A; Botta-Fridlund D; Coilly A; Samuel D; Duclos-Vallée JC; Pageaux GP
Liver Transpl; 2016 Oct; 22(10):1367-78. PubMed ID: 27348086
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience.
Yosry A; Gamal Eldeen H; Medhat E; Mehrez M; Zayed N; Elakel W; Abdelmoniem R; Kaddah M; Abdelaziz A; Esmat G; El-Serafy M; Doss W
J Med Virol; 2019 Apr; 91(4):668-676. PubMed ID: 30549048
[TBL] [Abstract][Full Text] [Related]
28. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.
Poordad F; Schiff ER; Vierling JM; Landis C; Fontana RJ; Yang R; McPhee F; Hughes EA; Noviello S; Swenson ES
Hepatology; 2016 May; 63(5):1493-505. PubMed ID: 26754432
[TBL] [Abstract][Full Text] [Related]
29. Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.
Beinhardt S; Al-Zoairy R; Kozbial K; Stättermayer AF; Maieron A; Stauber R; Strasser M; Zoller H; Graziadei I; Rasoul-Rockenschaub S; Trauner M; Ferenci P; Hofer H
Liver Int; 2018 Jul; 38(7):1188-1197. PubMed ID: 29197145
[TBL] [Abstract][Full Text] [Related]
30. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network.
Brown RS; O'Leary JG; Reddy KR; Kuo A; Morelli GJ; Burton JR; Stravitz RT; Durand C; Di Bisceglie AM; Kwo P; Frenette CT; Stewart TG; Nelson DR; Fried MW; Terrault NA;
Liver Transpl; 2016 Jan; 22(1):24-33. PubMed ID: 26519873
[TBL] [Abstract][Full Text] [Related]
31. Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.
Maasoumy B; Vermehren J; Welker MW; Bremer B; Perner D; Höner Zu Siederdissen C; Deterding K; Lehmann P; Cloherty G; Reinhardt B; Pawlotsky JM; Manns MP; Zeuzem S; Cornberg M; Wedemeyer H; Sarrazin C
J Hepatol; 2016 Sep; 65(3):473-82. PubMed ID: 27085252
[TBL] [Abstract][Full Text] [Related]
32. Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis.
El Raziky M; Gamil M; Ashour MK; Sameea EA; Doss W; Hamada Y; Van Dooren G; DeMasi R; Keim S; Lonjon-Domanec I; Hammad R; Hashim MS; Hassany M; Waked I
J Viral Hepat; 2017 Feb; 24(2):102-110. PubMed ID: 27790789
[TBL] [Abstract][Full Text] [Related]
33. Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.
Donato MF; Morelli C; Romagnoli R; Invernizzi F; Mazzarelli C; Iemmolo RM; Montalbano M; Lenci I; Bhoori S; Pieri G; Berardi S; Caraceni P; Martini S;
Liver Int; 2017 May; 37(5):678-683. PubMed ID: 27865034
[TBL] [Abstract][Full Text] [Related]
34. Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study.
Bruno G; Saracino A; Fabrizio C; Scudeller L; Milano E; Dell'Acqua R; Ladisa N; Fasano M; Minniti S; Buccoliero G; Tartaglia A; Giammario A; Milella M; Angarano G
Int J Antimicrob Agents; 2017 Mar; 49(3):296-301. PubMed ID: 28163136
[TBL] [Abstract][Full Text] [Related]
35. INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
Castedal M; Segenmark M; Cederberg S; Skoglund C; Weiland O
Scand J Gastroenterol; 2017 May; 52(5):585-588. PubMed ID: 28270038
[TBL] [Abstract][Full Text] [Related]
36. Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.
Willemse SB; Baak LC; Kuiken SD; van der Sluys Veer A; Lettinga KD; van der Meer JT; Depla AC; Tuynman H; van Nieuwkerk CM; Schinkel CJ; Kwa D; Reesink HW; van der Valk M
J Viral Hepat; 2016 Dec; 23(12):950-954. PubMed ID: 27405785
[TBL] [Abstract][Full Text] [Related]
37. Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients.
Kwok RM; Ahn J; Schiano TD; Te HS; Potosky DR; Tierney A; Satoskar R; Robertazzi S; Rodigas C; Lee Sang M; Wiegel J; Patel N; Gripshover J; Hassan MA; Branch A; Smith CI
Liver Transpl; 2016 Nov; 22(11):1536-1543. PubMed ID: 27543748
[TBL] [Abstract][Full Text] [Related]
38. Impact of Sofosbuvir-Based Regimens for the Treatment of Hepatitis C After Liver Transplant on Renal Function: Results of a Canadian National Retrospective Study.
Faisal N; Bilodeau M; Aljudaibi B; Hirch G; Yoshida EM; Hussaini T; Ghali MP; Congly SE; Ma MM; Lilly LB
Exp Clin Transplant; 2019 Feb; 17(1):59-63. PubMed ID: 29619910
[TBL] [Abstract][Full Text] [Related]
39. Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.
Del Bello D; Cha A; Sorbera M; Bichoupan K; Levine C; Doyle E; Harty A; Patel N; Ng M; Gardenier D; Odin J; Schiano TD; Fierer DS; Berkowitz L; Perumalswami PV; Dieterich DT; Branch AD
Clin Infect Dis; 2016 Jun; 62(12):1497-1504. PubMed ID: 26936665
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting.
Abaalkhail F; Elsiesy H; Elbeshbeshy H; Shawkat M; Yousif S; Ullah W; Alabbad S; Al-Jedai A; Ajlan A; Broering D; Saab S; Al Sebayel M; Al-Hamoudi W
Transplantation; 2017 Nov; 101(11):2739-2745. PubMed ID: 28795982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]